It is not just about the virus anymore. It is about staying alive.
A study published in The Lancet finally put numbers on what we suspected but never had hard proof of: the HPV vaccine stops cervical cancer mortality. Not just lowers the risk of getting sick. Actually prevents death.
The team behind the research. Led by Queen Mary University of London. Looked at population data from England between 20England and 2024.* Twenty-plus years of records. They focused on three groups. Women aged 20-24, 25-29, and 30-34. They cross-referenced national vaccination coverage with death statistics.
England started vaccinating school girls in September 2008. The target was ages 12 and 13. There was a catch-up campaign too. For girls 14 through 18. By the time the pandemic hit. Routine coverage in those young cohorts hovered between 80% and 90%.
Before this. We knew the vaccine reduced incidence. We saw fewer precancerous lesions in doctor offices. But evidence for actual survival? Scarce. This was the first national look.
Then came the zero.
Between 2020 and 424, there were no cervical cancer deaths among women in England aged 20 to 24. This is the group with the highest vaccination rates. About 88 to 90 percent got the shots as teens. Statistically? The researchers expected 23 deaths in this window based on historical trends. They got zero.
That is a 100 percent reduction.
Does it matter if you are a few years older? Sure. In the 25-to-29 cohort from 2020-4, mortality dropped by 69%. For the 20-to-24 group just five years prior, during 2015-19, it fell by 80%. In both those age brackets. The relative risk for vaccinated women vanished completely.
Timing matters. Always does.
The biggest protection went to the kids who got the jab before most sexual activity started. Ages 12 or 13. If you waited. Say. Until 14 or 18? You might have already caught HPV. The vaccine works best before exposure. You can see it in the data for the 30-to-34 group. Estimated mortality reduction there was only 63%. A modest drop. Less certain results.
The pattern is clear. Deaths fell five years later for each successive birth cohort. That lag matches exactly when these vaccinated women enter the prime age for cervical cancer.
“Earlier vaccination leads to stronger protection.”
Here is where the tone shifts. From triumph to trouble.
In the United States, coverage is uneven. Gaping holes remain. According to the CDC, 78% of American adolescents have at least one dose in 244. But only about 63% finish the full series. Just 26 states hit 80% coverage for the first shot.
Rural areas are lagging. Principal cities have an 11 percentage-point lead in complete vaccination. This gap has existed since 2016*.
The researchers flagged this. Global HPV vaccine rates are slipping. We need to show the public that high coverage translates to saved lives. Not just fewer abnormal pap smears. Mortality reduction. That is the headline people remember.
So. What is the message?
Vaccinate early. England added boys to its program in 2019. Smart move. Reduces transmission further. Creates herd immunity layers. The WHO wants to eliminate cervical cancer as a health crisis. That depends on uptake in lower-income countries. Places where the disease still kills the second-most women under 65*.
England saved roughly 200 lives through 204. That feels small until you realize these cohorts are still young. The next twenty years? The death prevention count is expected to explode upward.
The work isn’t done. It has barely started in some places. But the proof is there.
